Emerging Detail
LTGO - Latigo Biotherapeutics, Inc.
SNF Emerging Watchlist(TM) tracks newly public companies positioned around emerging economic themes. Inclusion reflects SNF research interest and ongoing monitoring; it is not a recommendation to buy, sell, or hold a security.
Emerging Score
80 / 100
Confidence
92%
Band
Strong Emerging Profile
Last Reviewed
Oct 23, 2026
Primary Theme
Biotechnology / Health Innovation
Exchange
Nasdaq
Current Thesis
Structural Theme Relevance
What Changed
Candidate to Candidate review completed.
Why It Matters
Structural Theme Relevance
What The Market Is Pricing In
Market Confirmation currently scores 50/100 within the Emerging Score framework.
What Could Change The Narrative
Phase 3 execution and reproducing efficacy at pivotal scale
SNF Lens
Signal
Structural Theme Relevance
Noise
Some evidence needs refresh context.
Confirmation
Market Confirmation 50/100
Risk
Phase 3 execution and reproducing efficacy at pivotal scale
Six-Family Scorecard
82
82
88
80
88
50
Key Risks
Phase 3 execution and reproducing efficacy at pivotal scale
Clinical safety, timeline slippage and long-term financing needs
Evidence Quality
Active Evidence
6
Sources
3
Stale Evidence
1
Freshness
Mixed freshness
Review / Score History
Oct 23, 2026Thesis unchanged - Candidate unchanged
Oct 4, 2026Thesis unchanged - Candidate unchanged
Sep 18, 2026Thesis strengthened - Candidate unchanged
Oct 23, 2026Score 80 / Confidence 92 / Candidate
Oct 4, 2026Score 80 / Confidence 92 / Candidate
Sep 18, 2026Score 80 / Confidence 92 / Candidate
Sep 1, 2026Score 79 / Confidence 88 / Candidate
Sources
Market Data
market-data - Sep 17, 2026